Validation of Group B Borderline Resectable Pancreatic Cancer: Retrospective Analysis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Among borderline resectable pancreaticcancer (BRPC), group B BRPC patients have findings that aresuggestive but not diagnostic of metastasis. In this study, weattempted to validate whether group B could truly be categorizedas a borderline resectable group. Methods: We placedthe BRPC patients into group A or group B. The survival outcomeswere compared between the groups. Results: A totalof 53 patients with pancreatic adenocarcinoma was classifiedas either group A or B borderline resectable. In groupA, 23 (60.5%) of 38 patients underwent pancreatectomyafter concurrent chemoradiotherapy or chemotherapy, but ingroup B, only five (33.3%) of 15 patients underwent pancreatectomy,mainly because of the progression of suspecteddistant metastasis. There was a significant difference inoverall survival (OS) between group A and B patients (medianOS, 21.2 months vs 10.2 months, respectively; p=0.007). Ofthe patients who underwent pancreatectomy, group B hada higher recurrence rate compared to group A (recurrencerate: 11 of 23 patients [47.8%] vs five of five patients [100%],respectively; p=0.033). Conclusions: This report is the firstto validate the definition of BPRC. Group B had much worseoutcomes, and whether group B BRPC can be categorizedas BRPC together with group A is questionable.
Abstract
Background/Aims: Among borderline resectable pancreaticcancer (BRPC), group B BRPC patients have findings that aresuggestive but not diagnostic of metastasis. In this study, weattempted to validate whether group B could truly be categorizedas a borderline resectable group. Methods: We placedthe BRPC patients into group A or group B. The survival outcomeswere compared between the groups. Results: A totalof 53 patients with pancreatic adenocarcinoma was classifiedas either group A or B borderline resectable. In groupA, 23 (60.5%) of 38 patients underwent pancreatectomyafter concurrent chemoradiotherapy or chemotherapy, but ingroup B, only five (33.3%) of 15 patients underwent pancreatectomy,mainly because of the progression of suspecteddistant metastasis. There was a significant difference inoverall survival (OS) between group A and B patients (medianOS, 21.2 months vs 10.2 months, respectively; p=0.007). Ofthe patients who underwent pancreatectomy, group B hada higher recurrence rate compared to group A (recurrencerate: 11 of 23 patients [47.8%] vs five of five patients [100%],respectively; p=0.033). Conclusions: This report is the firstto validate the definition of BPRC. Group B had much worseoutcomes, and whether group B BRPC can be categorizedas BRPC together with group A is questionable.
참고문헌 (18)
- Varadhachary GR, "Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy", Ann Surg Oncol, 13, pp.1035~1046 (2006)
- Katz MH, "Borderline resectable pancreatic cancer: the importance of this emerging stage of disease", J Am Coll Surg, 206, pp.833~846 (2008)
- Katz MH, "Borderline resectable pancreatic cancer: what have we learned and where do we go from here?", Ann Surg Oncol, 18, pp.608~610 (2011)
- Sharma J, "New developments in the management of borderline resectable pancreatic cancer", JOP, 14, pp.123~125 (2013)
- Kang CM, "Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer", J Gastrointest Surg, 16, pp.509~517 (2012)
- Kalser MH, "Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection", Arch Surg, 120, pp.899~903 (1985)
- Klinkenbijl JH, "Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group", Ann Surg, 230, pp.776~782 (1999)
- Neoptolemos JP, "Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial", Lancet, 358, pp.1576~1585 (2001)
- Regine WF, "Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup", RTOG 9704 phase III trial, 2011, pp.18, 1319~1326
- Evans DB, "Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy", Ann Surg Oncol, 17, pp.2803~2805 (2010)
- Varadhachary GR, "Preoperative therapies for resectable and borderline resectable pancreatic cancer", J Gastrointest Oncol, 2, pp.136~142 (2011)
- Jia Y, "Management of borderline resectable pancreatic adenocarcinoma", JOP, 13, pp.147~150 (2012)
- Callery MP, "Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement", Ann Surg Oncol, 16, pp.1727~1733 (2009)
- Tzeng CW, "Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy", Ann Surg Oncol, 19, pp.2045~2053 (2012)
- Springett GM, "Borderline resectable pancreatic cancer: on the edge of survival", Cancer Control, 15, pp.295~307 (2008)
- Asiyanbola B, "Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio", J Gastrointest Surg, 13, pp.752~759 (2009)
- Sperti C, "Recurrence after resection for ductal adenocarcinoma of the pancreas", World J Surg, 21, pp.195~200 (1997)
- Takahashi S, "Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment", J Hepatobiliary Pancreat Sci, 18, pp.567~574 (2011)